Dekabank Deutsche Girozentrale Reduces $157K in Alector, Inc. ($ALEC)
Key Points
- Dekabank Deutsche Girozentrale changed its Alector, Inc. ($ALEC) stake by 100.0% last quarter, cutting to 0 shares.
- $ALEC last traded around $1.57.
Dekabank Deutsche Girozentrale reduced its position in Alector, Inc. ($ALEC), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Alector, Inc. after selling 100,000 shares during the quarter.
Alector, Inc. ($ALEC) Stock
Alector, Inc. Earnings
Analysts Set New Price Targets
About Alector, Inc.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.